EFSA Renders Positive Opinion on Choline Health Claims in the European Union
May 04 2011 - 2:30PM
Balchem Corporation (Nasdaq:BCPC)
completes European expansion in support of human grade
choline.
On April 8, 2011, the European Food Safety Authority (EFSA),
through its Panel on Dietetic Products, Nutrition and Allergies,
issued a scientific opinion on Balchem's proposed Article 13
general health claims, supporting the benefits of the nutrient
Choline. The report concluded that Choline is an important dietary
component that contributes to the maintenance of normal liver
function, normal metabolism of lipids and homocysteine. The
dossiers submitted by Balchem, in support of these claims, were
deemed sufficient for substantiation by EFSA. This positive
recommendation is now subject to formal approval by the European
Union expected in the coming months. "This EFSA announcement
further establishes Choline as an important nutrient providing many
physiological benefits effective for the general population. It
also builds upon the worldwide recognition that Choline is
advantageous for normal fetal and infant development. It is simply
Essential for Every BodySM," said Dr. Kristine Lukasik Manager of
Regulatory and Scientific Affairs at Balchem.
"Furthermore we are excited about the timeliness of these
announcements," said Cheryl Pasiut, Business Director Nutrients.
"In parallel with our dossier submissions, we have completed the
necessary capital investments, to our Choline manufacturing
facility in Marano Italy, in support of the anticipated increase in
consumer demand for supplement and food products containing
VitacholineTM."
Segment Information
Balchem Corporation consists of three business segments: ARC
Specialty Products; Food, Pharma & Nutrition; and Animal
Nutrition & Health. Through ARC Specialty Products, Balchem
provides specialty-packaged chemicals for use in healthcare and
other industries. The Food, Pharma & Nutrition segment provides
proprietary microencapsulation solutions to a variety of
applications in the human food, pharmaceutical and nutrition
marketplaces. The Animal Nutrition & Health segment
manufactures and supplies products to numerous animal health
markets and certain derivative products into industrial
applications.
Forward-Looking Statements
This release contains forward-looking statements, which reflect
Balchem's expectation or belief concerning future events that
involve risks and uncertainties. Balchem can give no assurance that
the expectations reflected in forward-looking statements will prove
correct and various factors could cause results to differ
materially from Balchem's expectations, including risks and factors
identified in Balchem's annual report on Form 10-K for the year
ended December 31, 2010. Forward-looking statements are qualified
in their entirety by the above cautionary statement. Balchem
assumes no duty to update its outlook or other forward-looking
statements as of any future date.
CONTACT: Karin McCaffery
845 326 5600
Balchem (NASDAQ:BCPC)
Historical Stock Chart
From May 2024 to Jun 2024
Balchem (NASDAQ:BCPC)
Historical Stock Chart
From Jun 2023 to Jun 2024